Syneos Health, Inc. (NASDAQ:SYNH) Stock Position Lifted by Bank of Montreal Can

Posted by on Apr 28th, 2023

Bank of Montreal Can grew its position in shares of Syneos Health, Inc. (NASDAQ:SYNH – Get Rating) by 4.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 32,400 shares of the company’s stock after buying an additional 1,408 shares during the period. Bank of Montreal Can’s holdings in Syneos Health were worth $1,188,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the company. Lindbrook Capital LLC lifted its holdings in shares of Syneos Health by 898.7% in the 4th quarter. Lindbrook Capital LLC now owns 769 shares of the company’s stock worth $28,000 after purchasing an additional 692 shares during the last quarter. CWM LLC lifted its holdings in shares of Syneos Health by 51.7% in the 3rd quarter. CWM LLC now owns 634 shares of the company’s stock worth $30,000 after purchasing an additional 216 shares during the last quarter. Wipfli Financial Advisors LLC bought a new stake in shares of Syneos Health in the 3rd quarter worth approximately $31,000. Rockefeller Capital Management L.P. lifted its holdings in shares of Syneos Health by 147.1% in the 3rd quarter. Rockefeller Capital Management L.P. now owns 897 shares of the company’s stock worth $42,000 after purchasing an additional 534 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new stake in shares of Syneos Health in the 3rd quarter worth approximately $45,000. Institutional investors own 93.51% of the company’s stock.

Syneos Health Stock Up 0.3 %

Shares of SYNH opened at $37.85 on Friday. The stock has a market cap of $3.91 billion, a price-to-earnings ratio of 14.73 and a beta of 1.61. The company has a quick ratio of 1.13, a current ratio of 1.13 and a debt-to-equity ratio of 0.76. Syneos Health, Inc. has a 12 month low of $22.89 and a 12 month high of $79.77. The company has a 50-day moving average price of $37.32 and a two-hundred day moving average price of $37.49.

Syneos Health (NASDAQ:SYNH – Get Rating) last posted its earnings results on Thursday, February 16th. The company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.07 by $0.08. Syneos Health had a net margin of 4.94% and a return on equity of 13.19%. The company had revenue of $1.36 billion during the quarter, compared to analysts’ expectations of $1.29 billion. Equities analysts predict that Syneos Health, Inc. will post 2.85 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts recently issued reports on the company. Robert W. Baird raised their price target on Syneos Health from $42.00 to $51.00 and gave the stock an “outperform” rating in a report on Friday, February 17th. StockNews.com started coverage on Syneos Health in a research note on Thursday, March 16th. They set a “hold” rating on the stock. Mizuho reaffirmed a “neutral” rating and set a $38.00 target price on shares of Syneos Health in a research note on Friday, February 17th. JPMorgan Chase & Co. downgraded Syneos Health from a “neutral” rating to an “underweight” rating and cut their target price for the company from $30.00 to $28.00 in a research note on Monday, February 13th. Finally, Barclays cut their target price on Syneos Health from $45.00 to $37.00 and set an “underweight” rating on the stock in a research note on Tuesday, April 4th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $50.78.

Syneos Health Profile

(Get Rating)

Syneos Health, Inc engages in the provision of biopharmaceutical solutions. It operates through the Clinical Solutions and Commercial Solutions segments. The Clinical Solutions segment offers global services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics that span Phase I to IV of clinical development.

Recommended Stories

Institutional Ownership by Quarter for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.